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Abstract
Introduction
A national diabetic retinopathy screening program does not exist
in Mexico as of 2017. Our objective was to develop a screening
tool based on a predictive model for early detection of diabetic ret-
inopathy in a low-income population.
Methods
We  analyzed  biochemical,  clinical,  anthropometric,  and  so-
ciodemographic information from 1,000 adults with diabetes in
low-income communities in Mexico (from 11,468 adults recruited
in 2014–2016). A comprehensive ophthalmologic evaluation was
performed. We developed the screening tool through the follow-
ing stages: 1) development of a theoretical predictive model, 2)
performance assessment and validation of the model using cross-
validation and the area under the receiver operating characteristic
curve (AUC ROC), and 3) optimization of cut points for the clas-
sification of diabetic retinopathy. We identified points along the
AUC ROC that minimized the misclassification cost function and
considered various scenarios of misclassification costs and diabet-
ic retinopathy prevalence.
Results
Time since diabetes diagnosis, high blood glucose levels, systolic
hypertension, and physical inactivity were considered risk factors
in our screening tool.  The mean AUC ROC of our model was
0.780 (validation data set). The optimized cut point that best rep-
resented our study population (z = −0.640) had a sensitivity of
82.9% and a specificity of 61.9%.
Conclusion
We developed a low-cost and easy-to-apply screening tool to de-
tect  people at  high risk of diabetic retinopathy in Mexico. Al-
though  classification  performance  of  our  tool  was  acceptable
(AUC ROC > 0.75), error rates (precision) depend on false-negat-
ive and false-positive rates. Therefore, confirmatory assessment of
all cases is mandatory.
Introduction
In 2016, diabetes was declared a national epidemiologic emer-
gency in Mexico (1). In 2006, the estimated prevalence of dia-
betes in Mexican adults was 14.4% (2). Mortality rates attribut-
able to this disease in Mexico are among the highest in the world
(3). By 2012, 74.7% of Mexican adults with diagnosed diabetes
had inadequate glycemic control (4). Diabetes is associated with
the development and progression of diabetic retinopathy (5–8), a
major cause of sight loss and blindness in Latin American coun-
tries (9).  A population-based survey from 2010 in the state of
Chiapas found that 38.9% of adults aged 50 or older with diabetes
had diabetic retinopathy and 21.0% had proliferative diabetic ret-
inopathy (10).
Long-term diabetes and hypertension are consistently associated
with diabetic retinopathy (5–8,11–13). The Mexican National Nu-
trition Survey 2006 found that the mean time since diabetes dia-
gnosis among adults was more than 8 years (2). In 2012, an estim-
ated 65.6% of adults with diabetes had hypertension (14). In this
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context, an epidemic of diabetes complications, including diabetic
retinopathy, could worsen in Mexico, and the study of screening
systems for diabetic retinopathy is important.
Diabetic retinopathy ranks third in direct costs generated by dia-
betes complications in Mexico (15); these costs result from spe-
cialized procedures for diagnosis and treatment. A cost-benefit
analysis to identify optimal cut points for identifying people who
are at risk for diabetic retinopathy and who need a comprehensive
ophthalmologic evaluation is an approach to developing an ad-
equate-performance screening tool (16);  however,  such an ap-
proach would be complex because of the detailed cost informa-
tion required.
Our objective was to develop a practical screening tool based on a
predictive model and a simplification of a cost-benefit analysis to
optimize cut points for early detection of diabetic retinopathy in
low-income communities in Mexico.
Methods
We conducted a screening protocol for eye-related complications
of diabetes from May 1, 2014, to June 30, 2016, in 3 low-income
municipalities in the state of Morelos. We recruited 11,468 adults
(aged ≥20 y) for a screening of chronic diseases in our mobile unit
and community health centers. From these participants, we in-
vited those with a type 2 diabetes diagnosis (n = 1,768 [15.4%]) to
a comprehensive ophthalmologic evaluation. Exclusion criteria for
this evaluation were signs of ocular infection or pregnancy.
Of the 1,768 participants, 538 declined to participate in the oph-
thalmologic evaluation, 1 person was excluded because the qual-
ity of photographs was not adequate for grading, and 229 parti-
cipants did not have a photographic assessment at the time of ana-
lysis. One thousand participants (56.6%) completed the procedure.
We obtained informed consent from all participants, and the pro-
tocol was approved by the ethics, research, and biosecurity com-
mittees of the Mexican National Institute of Public Health.
Data collection and definition of variables
All participants had at least 1 glycemic assessment (fasting [≥8 h]
capillary or random capillary glycemia [glucometer method] or
fasting venous glycemia [glucose oxidase method]). Fasting ser-
um triglycerides, total cholesterol, and high-density lipoprotein
cholesterol were assessed by enzymatic method (n = 418) and ser-
um insulin with radioimmunoassay method (n = 112) for a portion
of the sample; because of logistical and budgetary constraints, the
entire sample could not be assessed for these variables.
High blood glucose was defined as a fasting glucose of 126 mg/dL
or more or, if fasting glucose was unavailable, as random glucose
of 200 mg/dL or more (17). Insulin resistance was classified by
using a homeostasis model assessment value of 3.8 or more (18).
Hypertriglyceridemia was defined as triglycerides of 150 mg/dL
or more, hypercholesterolemia as total cholesterol of 200 mg/dL
or more, and hypoalphalipoproteinemia as high-density lipopro-
tein cholesterol of less than 50 mg/dL for women and less than 40
mg/dL for men (19,20).
Blood pressure was measured twice (interval of 30 seconds). We
diagnosed high systolic/diastolic blood pressure when the average
of the assessments was ≥140/≥90 mm Hg. Likewise, we recorded
whether participants reported a diagnosis of hypertension (21).
Weight, height, and waist circumference were measured by trained
personnel  using  standard  protocols.  Body  mass  index  (BMI;
weight in kilograms divided by height in m2 [kg/m2]) was calcu-
lated:  overweight  was  defined  as  a  BMI  of  25.0  to  29.9  and
obesity as a BMI of 30.0 or more (22). Abdominal obesity was
defined as a waist circumference of 80 cm or more for women and
90 cm or more for men (19).
Data on sociodemographic characteristics and clinical history were
collected by trained interviewers through an adapted version of the
questionnaires applied in the National Health and Nutrition Sur-
vey of Mexico (23). We used the time since diabetes diagnosis as
a proxy of duration of type 2 diabetes and categorized it into 4 in-
tervals (<5 y, 5 y to <10 y, 10 y to <15 y and ≥15 y). Participants
reported whether they followed diet and physical activity recom-
mendations to control their diabetes.
We conducted a principal component analysis of 15 characterist-
ics related to household appliances and services (eg, ownership of
car, telephone, computer, vacuum cleaner, washing machine, refri-
gerator,  pay television, internet) as a proxy for socioeconomic
status (SES). Similar methods have been used (14). These charac-
teristics had a factorial loading of 0.30 or more. The first principal
component was divided into tertiles and used as a proxy for low
SES, medium SES, and high SES.
Ophthalmologic evaluation
All participants were interviewed by using a validated question-
naire for ocular assessment. The following data were collected by
trained technicians: best-corrected visual acuity, refractometry (by
using an automated refractor [Huvitz HRK-7000]), and intraocu-
lar pressure (by using a rebound tonometer [Icare TA01i]). After-
wards, all participants received a photographic evaluation of their
posterior  pole  (45°  nonmydriatic  fundus  camera  [DRS-
Centervue]). Participants were dilated with tropicamide only if the
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quality of the photographs was not adequate for grading. We took
3 fields of the posterior pole using a standardized protocol. The
first field centered on the optic nerve, the second field centered on
the fovea, and third field was temporal to the macula but included
the fovea. This protocol has an adequate level of sensitivity and
specificity for grading referable stages of diabetic retinopathy
(24).
All photographs were sent to Eye Knowledge Network (www.eye-
knowledge.net). All cases were masked and reviewed by trained
graders from the Hospital Luis Sánchez Bulnes of the Association
for the Prevention of Blindness in Mexico. The cases were graded
by using the Revised English Diabetic Eye Screening Program
Grading System (25), which allows prompt referral of proliferat-
ive stages of diabetic retinopathy and macular edema. Diabetic ret-
inopathy was recorded when a participant had background diabet-
ic retinopathy, preproliferative diabetic retinopathy, or proliferat-
ive diabetic retinopathy.
Statistical analysis
We tabulated categorical variables as frequency and proportion
distributions and quantitative variables as  measures of  central
tendency (mean or median) and dispersion (standard deviation
[SD] or interquartile range). We set statistical significance at an α
of .05. We compared measures of central tendency according to
diabetic retinopathy status of participants (has diabetic retino-
pathy or does not have diabetic retinopathy) by using the Student t
test or Mann–Whitney U test, depending on the distribution of the
quantitative variables. We used a χ2  test or Fisher exact test to
compare the prevalence of diabetic retinopathy across categories
of nonquantitative variables. We conducted a descriptive analysis
to compare sociodemographic and clinical characteristics and dia-
betic retinopathy risk factors between participants and nonparti-
cipants.
We developed the screening tool in 3 stages: 1) we developed the
theoretical predictive model, 2) we assessed the performance of
the model and conducted a validation analysis, and 3) we optim-
ized risk-score cut points for diabetic retinopathy classification.
Development of the theoretical predictive model
For multivariate analysis, we included only participants who had
complete information on diabetic retinopathy status (the depend-
ent variable), and we determined whether at least 95% of the parti-
cipants provided information for each of the independent vari-
ables. If 5% or more of the participants did not provide informa-
tion for an independent variable (theoretical risk factors of diabet-
ic retinopathy), we used multiple imputation through a logistic re-
gression model, where diabetic retinopathy, sex, age, and self-re-
ported diabetes screening were the independent variables, to com-
plete the information.
We generated a predictive probit model based on theoretical risk
factors of diabetic retinopathy (5–8,11–13). We decided to use this
model to develop our tool because of its easy interpretability as a z
score from its linear equation and because it provides a predicted
probability for the linear predictor (applying the standard normal
cumulative function). Familiarity with this distribution provides a
better understanding of coefficients and predicted z scores. The
dependent variable was diabetic retinopathy, and the 4 predictors
were  time  since  diabetes  diagnosis,  high  blood  glucose,  high
systolic  blood pressure,  and physical  inactivity.  We estimated
probabilities adjusted by covariables of having diabetic retino-
pathy given each risk factor category though predictive margins.
Performance assessment and validation
We used the k-fold cross-validation method (k = 10 partitions) and
the area under the receiver operating characteristic curve (AUC
ROC). To assess the performance of the model in training and val-
idation data sets, we randomly divided the sample into 10 parti-
tions. In each partition, one segment was reserved for model valid-
ation (validation data set, n ~ 10%), while the rest of the sample in
this partition was used as a training subsample (training data set, n
~ 90%). We calculated the AUC ROC for each iteration and its
mean for the 10 iterations.
Optimization of risk-score cut points for diabetic
retinopathy classification
We developed a risk score for diabetic retinopathy based on the z
predictor of  our statistical  model.  In this  way,  the attributable
score of each risk factor was equivalent to its probit coefficient.
The use  of  a  cost-benefit  analysis  to  select  cut  points  implies
knowledge of true and false classification costs; however, it is dif-
ficult to have such complete information. To select the optimal cut
points of the z predictor to classify diabetic retinopathy, we de-
cided to focus on misclassification costs only through the misclas-
sification cost  term (16).  We identified points  along the ROC
curve that minimized the misclassification cost function for vari-
ous scenarios of misclassification costs and diabetic retinopathy
prevalence. The costs of true classification were assumed as null,
and the examples of the variations of misclassification ratios were
set according to consequences in health costs of screening for dia-
betic retinopathy.
We estimated sensitivity and specificity across AUC ROC and iso-
cost curves, which minimized the costs of misclassification. Like-
wise, we estimated positive predictive values and negative predict-
ive values.
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We considered the following scenarios for the optimization of the
cut points: diabetic retinopathy prevalence of 35.0%, 40.0%, and
45.0%, and the observed prevalence in our sample. We examined
various ratios of cost misclassification (classification costs of false
negatives divided by classification costs of false positives). We
examined ratios of 1, 4, and 10, assuming that classification of a
false negative would generate higher health care costs than would
classification of a false positive.
The statistical analysis was conducted by using Stata version 13.1
(StataCorp LLC) and RStudio version 1.0.136 with the Optimal-
Cutpoints package.
Results
The mean age of our sample was 57.2 y (SD, 11.0 y), and 73.0%
were women. The prevalence of diabetic retinopathy was 31.7%
(Table 1); 18.9% had background diabetic retinopathy, 5.7% had
preproliferative diabetic retinopathy, and 7.1% of participants had
active proliferative diabetic retinopathy.
The prevalence of diabetic retinopathy was significantly higher
among participants with insulin resistance, high blood glucose,
and hypertension than among participants without those condi-
tions.  Participants  with  diabetic  retinopathy  had  significantly
longer times since diabetes diagnosis, higher blood glucose levels,
and higher systolic blood pressure than those without diabetic ret-
inopathy. In contrast, the prevalence of diabetic retinopathy was
lower among participants who were overweight or obese, had ab-
dominal obesity, or used physical activity to control their diabetes
than among participants without these characteristics. The preval-
ence of diabetic retinopathy was highest, by SES, in the lowest ter-
tile of SES and highest, by marital status, among divorced adults
(Table 1).
We found no significant  differences  in  the  distribution of  so-
ciodemographic characteristics, clinical characteristics, or diabetic
retinopathy risk factors between participants and nonparticipants.
Development and cross-validation of predictive
model
From all  independent  variables  included in  our  model,  except
physical activity (data were missing for 17.0% of participants),
had at least 95.0% of information. After multiple imputation ana-
lysis for physical activity, we obtained a probit model with 939
observations.
According to our multivariate analysis (Table 2), time since dia-
betes diagnosis was positively associated with the estimated prob-
ability of diabetic retinopathy. For example, the probability of dia-
betic  retinopathy  was  11.4%  (95%  confidence  interval  [CI],
7.9%–14.9%) when time since diabetes diagnosis was less than 5
years, whereas the probability was 56.0% (95% CI, 49.5%–62.6%)
when time since diabetes diagnosis was 15 years or more. Simil-
arly,  the probability of diabetic retinopathy was higher among
those with high blood glucose (35.6%) and high systolic blood
pressure  (37.4%)  than  among  those  without  those  conditions
(23.9% and 29.3%, respectively). On the other hand, participants
who reported using physical  activity to control  diabetes had a
lower predicted probability of diabetic retinopathy (25.4%) than
those who reported not using physical activity (34.8%).
According to the cross-validation analysis (Table 3), the diagnost-
ic performance of our model was similar between training data
sets (mean AUC ROC = 0.780) and validation data sets (mean
AUC ROC = 0.778).
Risk-score cut points for diabetic retinopathy
classification
According to the prevalence of diabetic retinopathy observed with
misclassification ratios of 1, 4, and 10, the optimal cut points were
−0.046, −0.640, and −1.209, respectively (Table 4).
Four points minimized the misclassification costs given the ROC
curve of our model (Figure). The optimized cut point according to
a misclassification ratio of 4 and the diabetic retinopathy preval-
ence observed in our sample (31.7%) was z = −0.640, with a sens-
itivity of 82.9%, a specificity of 61.9%, a positive predictive value
of 50.3%, and a negative predictive value of 88.6% (Table 4).
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Figure.  Area under  the receiver  operating characteristic  (ROC)  curve and
points along the ROC curve corresponding to optimized cut points given a cost
ratio (classification costs of false negatives divided by classification costs of
false  positives)  equal  to  4  and various  scenarios  of  diabetic  retinopathy
prevalence: a) 31.7%, the observed prevalence in the study population; b) and
c) prevalence of 35.0% and 40.0%; and d) prevalence of 45.0%.
 
On the basis of our data, we propose a risk-score screening tool
(Box): A health care provider (can be a nonspecialized provider)
asks the patient 2 questions (on time since diabetes diagnosis and
use of physical activity to control diabetes) and obtains 2 measure-
ments (blood glucose and systolic blood pressure). Each response
is scored, the scores are summed, and a final score is calculated.
The health care provider  consults  a  simple chart  that  shows 4
levels of diabetic retinopathy prevalence, chooses the prevalence
that most closely matches the prevalence of the community in
which the patient resides, and then identifies the cut point that cor-
responds with the prevalence. If the patient has a score equal to or
greater than the cut point, the patient should be directed to receive
a comprehensive ophthalmologic evaluation.
Box. Proposed Screening Tool for Diabetic Retinopathy in Mexican Adults
Aged ≥20 With Type 2 Diabetes, Given a Cost Ratio (Classification Costs of
False Negatives Divided by Classification Costs of False Positives) of 4
Application Instructions:
Check one box per question.1.
Sum the corresponding scores of each checked box and
then subtract 1.48.
2.
Use the cut point closest to the diabetic retinopathy preval-
ence of the population in which you are applying this tool.
3.
If the patient obtained a higher or equal score to the cut
point used, the patient must be referred to specialized
health services for a comprehensive ophthalmologic evalu-
ation.
4.
Risk Factors for Diabetic Retinopathy Score
The information of the following 2 questions must be obtained
by direct interview:
1. How long have you been diagnosed with type 2 diabetes?
<5 years □ 0
5 to 9 years □ 0.55
10 to 14 years □ 1.16
≥15 years □ 1.41
2. Do you use physical activity to control blood sugar?
No □ 0
Yes □ (If you checked yes for this question, you must
subtract 0.33)
−0.33
The information of the following 2 questions must be obtained
from measurements carried out by the interviewer:
3. The patient had fasting capillary or venous glucose higher or equal to
126 mg/dL or random capillary glucose higher or equal to 200 mg/dL?
No □ 0
Yes □ 0.41







If prevalence of diabetic retinopathy is close to 31.7%, then
cut point is −0.640
•
If prevalence of diabetic retinopathy is close to 35.0%, then
cut point is −1.017
•
If prevalence of diabetic retinopathy is close to 40.0%, then
cut point is −1.017
•
If prevalence of diabetic retinopathy is close to 45.0%, then
cut point is −1.190
•
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Discussion
We developed a practical screening tool for diabetic retinopathy
that could be used by nonspecialized health care personnel in low-
income settings. The tool requires information on 4 risk factors.
Other risk scores exist (26,27); unlike these, we optimized various
cut points according to misclassification costs and diabetic retino-
pathy prevalence. This optimization allows the application of this
tool in various contexts.
We assumed that classifying people as not having diabetic retino-
pathy  when  they  actually  have  the  condition  (false  negative)
would result in higher long-term health care costs than would clas-
sifying them with the disease when they do not have it (false posit-
ive), because without timely diagnosis and treatment, these people
are likely to progress to advanced stages of the condition. We re-
commend using the cut points for misclassification ratios of 4 and
10,  which gives  greater  importance to  sensitivity  than to  spe-
cificity. Although this recommendation substantially decreases
specificity, it does not imply negative health effects, because all
people with type 2 diabetes should receive an ophthalmologic
evaluation when diabetes is diagnosed (17).
Although the rate of false positives generated by our tool could in-
crease health care costs (as a result of comprehensive ophthalmo-
logic evaluations), the application of our tool could help improve
compliance with recommendations for obtaining these evaluations.
In addition, the benefits of timely diagnosis and treatment could
compensate for any increases in health care costs.
Although we did not have complete information for a cost-benefit
analysis, we showed how results changed when the relative im-
portance of the cost of false negatives (type 2 error) to the cost of
false positives (type 1 error) varied. We set false-negative rates to
be higher than false-positive rates because the health care costs
resulting from delays in diagnosis and treatment of false negatives
may be high in the context of the screening of diabetic retino-
pathy. Although the classification performance of our tool was ac-
ceptable (AUC ROC > 0.75), the precision of classification de-
pends on the false-negative rate and false-positive rate. Therefore,
confirmatory assessment of all cases is mandatory. Additionally,
the negative cases identified by this tool also are at some risk of
diabetic retinopathy, so periodic exploratory evaluations should be
performed in all patients with diabetes.
We presented misclassification ratios only as examples: different
ratios could be assumed for future research or in different con-
texts. Our study demonstrated a simplified approach for develop-
ing a screening tool based on a misclassification-cost criterion. Fu-
ture research should focus on the assignment of costs for the 4
classification types (true positives, true negatives, false positives,
and false negatives) on diabetic retinopathy screening context.
We found that systolic blood pressure and the lack of physical
activity were associated with diabetic retinopathy; some studies
showed that high systolic blood pressure is a potentially modifi-
able risk factor for diabetic retinopathy (7,12). Physical inactivity
could be another important modifiable risk factor for diabetic ret-
inopathy because it is associated with poor glycemic control (28).
Our study showed that a simple question about physical activity
can predict a significantly lower probability of diabetic retino-
pathy. Although the question cannot determine whether a person is
implementing this lifestyle recommendation, it may reflect aware-
ness and knowledge of self-care practices.
Consistent with other researchers (29,30), we observed a negative
effect of obesity on diabetic retinopathy. Participants with over-
weight and obesity had lower levels of blood glucose and less time
since diabetes diagnosis than did underweight and normal-weight
participants (data not shown). We believe that the negative effect
of obesity on diabetic retinopathy may be attributed to the fact that
people with excess weight are experiencing an earlier stage of dia-
betes than people with normal or low weight.
We found a higher proportion of women (73.0%) than men in our
study sample possibly because women engage in self-care prac-
tices and informal unpaid activities more than men do; this en-
gagement may have facilitated their attendance to the recruitment
process. We found a lower systolic blood pressure among women
than among men (data not shown), which, given the higher pro-
portion of women, could have underestimated the effect of systol-
ic blood pressure in our analysis.
Our study has limitations. We did not measure HbA1c, which pre-
vented us from adjusting our model by a variable of long-term gly-
cemic control. However, our model adequately predicted diabetic
retinopathy using parameters that are easier to measure and less
expensive than an HbA1c test, which is not available at all primary
health care service locations in Mexico.
An important portion of the population with type 2 diabetes may
not receive a diagnosis for years (17). In Mexico, almost half of
the population with diabetes is not diagnosed during routine health
care, and many of them have complications that indicate many
years of living with the disease (2). However, it was not possible
to assess how long our study participants had been living with dia-
betes. Because the onset of type 2 diabetes can occur at any point
during adulthood (random error), age is not the best indicator of
diabetes duration. Instead of age, we used time since diagnosis as
a variable for diabetes duration. Self-report of time since diabetes
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diagnosis may underestimate duration, but we considered it to be a
nondifferential  systematic error  that  did not  affect  our results.
People with type 2 diabetes may recall onset of their disease inac-
curately, but the inaccuracy is the same across the population of
people with diabetes, and recall of onset is independent of the dia-
betic retinopathy condition.
The high health cost of diabetic retinopathy in Mexico is due in
part to the lack of a program designed to prevent diabetes complic-
ations (15). A challenge for our team will be to develop pilot stud-
ies that evaluate the feasibility, functionality, and costs of offering
our screening tool at primary health care service locations as a
strategy for strengthening the system for ophthalmologic evalu-
ation of people with diabetes.
Early detection strategies must be implemented to reduce the bur-
den of diabetic retinopathy. Our new screening tool is a promising
approach and a practical strategy with an adequate performance to
detect risk of diabetic retinopathy in adults with type 2 diabetes in
low-income communities in Mexico.
Notes
The authors thank Luisa Torres-Sanchez, Selene Pacheco-Mir-
anda, and Hector Lamadrid-Figueroa and ophthalmologists Raul
Velez-Montoya and Gerardo García-Aguirre. This study was fun-
ded by the World Diabetes Foundation (WDF-13788), by a schol-
arship  from the  Mexican  Council  of  Science  and  Technology
(Spanish acronym: CONACYT),  and by National  Institutes of
Health–Fogarty RO3 project no. TW009061. The authors declare
no financial or personal conflict of interest.
Author Information
Corresponding Author: Simón Barquera, PhD, Instituto Nacional
de  Salud  Pública,  Cuernavaca,  Morelos,  México,  Avenida
Universidad  #655  Col.  Sta.  Ma.  Ahuacatitlán,  CP  62100.
Telephone: 52-777-329-30-17. Email: sbarquera@insp.mx.
Author Affiliations: 1Center for Nutrition and Health Research,
National Institute of Public Health, Cuernavaca, Morelos, México.
2Center for Evaluation and Surveys Research, National Institute of
Public Health, Cuernavaca, Morelos, México. 3Association for the
Prevention of Blindness in Mexico, México City, México.
References
Mexican  Ministry  of  Health.  Epidemiological  emergency
statement EE-4-2016 for all the states of Mexico due to the
magnitude  and  transcendence  of  diabetes  mellitus  cases,
  1.
November  1,  2016.  Mexico  City  (MX):  Mexican  National
Center  for  Preventive  Programs  and  Disease  Control
(CENAPRECE); 2016. http://www.cenaprece.salud.gob.mx/
programas/interior/emergencias/descargas/pdf/EE_4.pdf.
Accessed August 23, 2017.
Villalpando S, de la Cruz V, Rojas R, Shamah-Levy T, Avila
MA, Gaona B,  et  al.  Prevalence and distribution of  type 2
diabetes mellitus in Mexican adult population: a probabilistic
survey. Salud Publica Mex 2010;52(Suppl 1):S19–26.
  2.
Barquera  S,  Pedroza-Tobias  A,  Medina  C.  Cardiovascular
diseases in mega-countries:  the challenges of  the nutrition,
physical activity and epidemiologic transitions, and the double
burden of disease. Curr Opin Lipidol 2016;27(4):329–44.
  3.
Jiménez-Corona A, Aguilar-Salinas CA, Rojas-Martínez R,
Hernández-Ávila  M.  Type  2  diabetes  and  frequency  of
prevention and control measures.  Salud Publica Mex 2013;
55(Suppl 2):S137–43.
  4.
Kim YJ,  Kim JG, Lee JY, Lee KS, Joe SG, Park JY, et  al.
Development  and  progression  of  diabetic  retinopathy  and
associated risk factors in Korean patients with type 2 diabetes:
the experience of a tertiary center. J Korean Med Sci 2014;
29(12):1699–705.
  5.
Mohamed Q, Gillies MC, Wong TY. Management of diabetic
retinopathy: a systematic review. JAMA 2007;298(8):902–16.
  6.
Liu Y, Wang M, Morris AD, Doney AS, Leese GP, Pearson
ER, et al. Glycemic exposure and blood pressure influencing
progression  and  remission  of  diabetic  retinopathy:  a
longitudinal cohort study in GoDARTS. Diabetes Care 2013;
36(12):3979–84.
  7.
Klein R, Klein BE, Moss SE, Cruickshanks KJ. The Wisconsin
Epidemiologic Study of Diabetic Retinopathy: XVII. The 14-
year incidence and progression of  diabetic retinopathy and
associated risk factors in type 1 diabetes. Ophthalmology 1998;
105(10):1801–15.
  8.
Limburg H, Espinoza R, Lansingh VC, Silva JC. Functional
low  vision  in  adults  from  Latin  America:  findings  from
population-based surveys in 15 countries. Rev Panam Salud
Publica 2015;37(6):371–8.
  9.
Polack S, Yorston D, López-Ramos A, Lepe-Orta S, Baia RM,
Alves L, et al. Rapid assessment of avoidable blindness and
diabetic retinopathy in Chiapas, Mexico. Ophthalmology 2012;
119(5):1033–40.
10.
Matthews DR, Stratton IM, Aldington SJ, Holman RR, Kohner
EM;  UK  Prospective  Diabetes  Study  Group.  Risks  of
progression of retinopathy and vision loss related to tight blood
pressure control in type 2 diabetes mellitus: UKPDS 69. Arch
Ophthalmol 2004;122(11):1631–40.
11.
Klein BE, Klein R, Moss SE, Palta M. A cohort study of the
relationship of diabetic retinopathy to blood pressure. Arch
Ophthalmol 1995;113(5):601–6.
12.
PREVENTING CHRONIC DISEASE VOLUME 14, E95
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY     OCTOBER 2017
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
www.cdc.gov/pcd/issues/2017/17_0157.htm • Centers for Disease Control and Prevention       7
Yau JW, Rogers SL, Kawasaki R, Lamoureux EL, Kowalski
JW, Bek T, et al. Global prevalence and major risk factors of
diabetic retinopathy. Diabetes Care 2012;35(3):556–64.
13.
Campos-Nonato I, Hernández-Barrera L, Rojas-Martínez R,
Pedroza  A,  Medina-García  C,  Barquera-Cervera  S.  [
Hypertension: prevalence, early diagnosis, control and trends
in  Mexican  adults].  Salud  Publica  Mex  2013;55(Suppl
2):S144–50.
14.
Barquera  S,  Campos-Nonato  I,  Aguilar-Salinas  C,  Lopez-
Ridaura R, Arredondo A, Rivera-Dommarco J.  Diabetes in
Mexico:  cost  and  management  of  diabetes  and  i ts
complications and challenges for health policy. Global Health
2013;9(1):3.
15.
López-Ratón M, Rodriguez-Álvarez MX, Cardaso-Suárez C,
Gude-Sampedro  F.  OptimalCutpoints:  an  R  package  for
selecting optimal cutpoints in diagnostic tests. J Stat Softw
2014;61(8).
16.
American Diabetes Association. 2. Classification and diagnosis
of diabetes. Diabetes Care 2017;40(Suppl 1):S11–24.
17.
Qu HQ, Li Q, Rentfro AR, Fisher-Hoch SP, McCormick JB.
The  definition  of  insulin  resistance  using  HOMA-IR  for
Americans of Mexican descent using machine learning. PLoS
One 2011;6(6):e21041.
18.
Alberti KG, Eckel RH, Grundy SM, Zimmet PZ, Cleeman JI,
Donato KA, et  al.  Harmonizing the metabolic syndrome: a
joint interim statement of the International Diabetes Federation
Task Force on Epidemiology and Prevention; National Heart,
Lung, and Blood Institute; American Heart Association; World
Heart Federation; International Atherosclerosis Society; and
International Association for the Study of Obesity. Circulation
2009;120(16):1640–5.
19.
National Cholesterol Education Program (NCEP) Expert Panel
on  Detection,  Evaluation,  and  Treatment  of  High  Blood
Cholesterol  in  Adults  (Adult  Treatment  Panel  III).  Third
Report of the National Cholesterol Education Program (NCEP)
Expert Panel on Detection, Evaluation, and Treatment of High
Blood Cholesterol in Adults (Adult Treatment Panel III) final
report. Circulation 2002;106(25):3143–421.
20.
Aronow  WS,  Fleg  JL,  Pepine  CJ,  Artinian  NT,  Bakris  G,
Brown  AS,  et  al.  ACCF/AHA  2011  expert  consensus
document  on  hypertension  in  the  elderly:  a  report  of  the
American College of Cardiology Foundation Task Force on
Clinical  Expert  Consensus  documents  developed  in
collaboration  with  the  American  Academy  of  Neurology,
American Geriatrics Society, American Society for Preventive
Cardiology,  American  Society  of  Hypertension,  American
Society of Nephrology, Association of Black Cardiologists,
and European Society of  Hypertension.  J  Am Coll  Cardiol
2011;57(20):2037–114.
21.
World Health Organization. Obesity: preventing and managing
the global epidemic. Report of a WHO consultation. Geneva
(CH):  World  Health  Organization;  2000.  Technical  report
series no. 894.
22.
Olaiz  G,  Rivera-Dommarco  JA,  Shamah-Levy  T,  Rojas-
Martínez  R,  Villalpando  S,  Hernández-Ávila  M:  Encuesta
Nacional de Salud y Nutrición 2006. Cuernavaca (Morelos):
2006.
23.
Vujosevic S, Benetti  E, Massignan F, Pilotto E, Varano M,
Cavarzeran F, et al. Screening for diabetic retinopathy: 1 and 3
nonmydriatic  45-degree  digital  fundus  photographs  vs  7
standard early treatment diabetic retinopathy study fields. Am J
Ophthalmol 2009;148(1):111–8.
24.
Broadbent D. Diabetic retinopathy: fundamentals for primary
care. Diabetes & Primary Care 2013;15(4):201–10.
25.
Wang J, Chen H, Zhang H, Yang F, Chen RP, Li YB, et al.
The  performance  of  a  diabetic  retinopathy  risk  score  for
screening for diabetic retinopathy in Chinese overweight/obese
patients  with  type  2  diabetes  mellitus.  Ann  Med  2014;
46(6):417–23.
26.
Azrak C, Palazón-Bru A, Baeza-Díaz MV, Folgado-De la Rosa
DM,  Hernández-Martínez  C,  Martínez-Toldos  JJ,  et  al.  A
predictive  screening  tool  to  detect  diabetic  retinopathy  or
macular edema in primary health care: construction, validation
and  implementation  on  a  mobile  application.  PeerJ  2015;
3:e1404.
27.
Umpierre D, Ribeiro PA, Kramer CK, Leitão CB, Zucatti AT,
Azevedo MJ, et al. Physical activity advice only or structured
exercise training and association with HbA1c levels in type 2
diabetes: a systematic review and meta-analysis. JAMA 2011;
305(17):1790–9.
28.
Klein  R,  Klein  BE,  Moss  SE.  Is  obesity  related  to
microvascular and macrovascular complications in diabetes?
The Wisconsin Epidemiologic Study of Diabetic Retinopathy.
Arch Intern Med 1997;157(6):650–6.
29.
Klein R, Klein BE, Moss SE, Davis MD, DeMets DL. The
Wisconsin epidemiologic study of diabetic retinopathy. III.
Prevalence  and  risk  of  diabetic  retinopathy  when  age  at
diagnosis  is  30  or  more  years.  Arch  Ophthalmol  1984;
102(4):527–32.
30.
PREVENTING CHRONIC DISEASE VOLUME 14, E95
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY     OCTOBER 2017
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
8       Centers for Disease Control and Prevention  •  www.cdc.gov/pcd/issues/2017/17_0157.htm
Tables
Table 1. Prevalence of Diabetic Retinopathya by Sociodemographic and Clinical Characteristics, and Means/Medians for Other Clinical Characteristics by Diabetic
Retinopathya Status of Study Population in 3 Low-Income Municipalities, Mexico, 2014–2016
Characteristics Total (N = 1,000)
Has Diabetic Retinopathy, %
(n = 317)
Does Not Have Diabetic
Retinopathy, % (n = 683) P Valueb
Overall 1,000 31.7 68.3
Sexc
Female 730 30.6 69.4
.20
Male 270 34.8 65.2
Socioeconomic statusc,d
Low 332 35.5 64.5
.04Middle 332 32.8 67.2
High 331 26.6 73.4
Marital statusc
Single 100 20.0 80.0
.01
Married 675 31.6 68.4
Divorced 77 41.6 58.4
Widowed 133 35.3 64.7
Can speak an indigenous languagec
Yes 47 34.0 66.0
.71
No 949 31.5 68.5
Educationc
None 162 34.6 65.4
.06
Some elementary school 454 33.5 66.5
Some junior high school 237 32.9 67.1
Some high school 82 23.2 76.8
Some bachelor’s degree or more 63 19.1 80.9
Health system affiliationc
None 83 30.1 69.9
.26
Abbreviations: HOMA, homeostasis model assessment; IMSS, the Mexican Social Security Institute (Spanish: Instituto Mexicano del Seguro Social); IQR, interquart-
ile range; ISSSTE, the Institute for Social Security and Services for State Workers (Spanish: Instituto de Seguridad y Servicios Sociales de los Trabajadores del Es-
tado).
a Diabetic retinopathy classification according to Revised English Diabetic Eye Screening Program Grading System (grade 1, grade 2, or grade 3) (25).
b χ2 test (contingency tables for more than 2 categories or proportion comparison), Student t test, or Mann–Whitney U test.
c The percentage of participants with missing data was <5.0% or with complete information.
d Socioeconomic index developed by using first principal component methodology.
e Prevalence of diabetic retinopathy was 32.5% among those measured for triglycerides, total cholesterol, and high-density lipoprotein cholesterol (n = 418).
f Prevalence of diabetic retinopathy was 25.9% among those measured for insulin (n = 112).
g The percentage of participants with missing data ≥5.0%.
h Determined by answer to question “Do you have any other treatment for sugar control?” Exercise (no/yes) and diet (yes/no) were provided as possible responses.
i Prevalence of diabetic retinopathy was 30.7% among those measured for fasting capillary glucose (n = 423).
j Prevalence of diabetic retinopathy was 31.6% among those measured for random capillary glucose (n = 402).
k Prevalence of diabetic retinopathy was 32.5% among those measured for fasting venous glucose (n = 418).
(continued on next page)
PREVENTING CHRONIC DISEASE VOLUME 14, E95
PUBLIC HEALTH RESEARCH, PRACTICE, AND POLICY     OCTOBER 2017
The opinions expressed by authors contributing to this journal do not necessarily reflect the opinions of the U.S. Department of Health and Human Services,
the Public Health Service, the Centers for Disease Control and Prevention, or the authors’ affiliated institutions.
www.cdc.gov/pcd/issues/2017/17_0157.htm • Centers for Disease Control and Prevention       9
(continued)
Table 1. Prevalence of Diabetic Retinopathya by Sociodemographic and Clinical Characteristics, and Means/Medians for Other Clinical Characteristics by Diabetic
Retinopathya Status of Study Population in 3 Low-Income Municipalities, Mexico, 2014–2016
Characteristics Total (N = 1,000)
Has Diabetic Retinopathy, %
(n = 317)
Does Not Have Diabetic
Retinopathy, % (n = 683) P Valueb
IMSS 150 27.3 72.7
ISSSTE 72 23.6 76.4
Seguro Popular 681 33.5 66.5
Private 13 46.2 53.8
Other 1 0.0 100.0
Body mass index,c kg/m2
<25.0 247 44.9 55.1
<.00125.0–29.9 416 30.8 69.2
≥30.0 321 23.1 76.9
Abdominal obesity (waist circumference ≥80 cm for women and ≥90 cm for men)c
Yes 869 30.4 69.6
.008
No 115 42.6 57.4
Triglycerides ≥150 mg/dLe
Yes 294 34.0 66.0
.32
No 124 29.0 70.1
Cholesterol ≥200 mg/dLe
Yes 168 37.5 62.5
.08
No 250 29.2 70.8
High-density lipoprotein cholesterol <50 mg/dL for women and <40 mg/dL for mene
Yes 329 31.3 68.7
.30
No 89 37.1 62.9
Insulin resistance HOMA index ≥3.8f
Yes 48 39.6 60.4
.004
No 64 15.6 84.4
High blood glucosec (fasting glucose ≥126 mg/dL or random glucose ≥200 mg/dL)
Yes 603 38.1 61.9
<.001
Abbreviations: HOMA, homeostasis model assessment; IMSS, the Mexican Social Security Institute (Spanish: Instituto Mexicano del Seguro Social); IQR, interquart-
ile range; ISSSTE, the Institute for Social Security and Services for State Workers (Spanish: Instituto de Seguridad y Servicios Sociales de los Trabajadores del Es-
tado).
a Diabetic retinopathy classification according to Revised English Diabetic Eye Screening Program Grading System (grade 1, grade 2, or grade 3) (25).
b χ2 test (contingency tables for more than 2 categories or proportion comparison), Student t test, or Mann–Whitney U test.
c The percentage of participants with missing data was <5.0% or with complete information.
d Socioeconomic index developed by using first principal component methodology.
e Prevalence of diabetic retinopathy was 32.5% among those measured for triglycerides, total cholesterol, and high-density lipoprotein cholesterol (n = 418).
f Prevalence of diabetic retinopathy was 25.9% among those measured for insulin (n = 112).
g The percentage of participants with missing data ≥5.0%.
h Determined by answer to question “Do you have any other treatment for sugar control?” Exercise (no/yes) and diet (yes/no) were provided as possible responses.
i Prevalence of diabetic retinopathy was 30.7% among those measured for fasting capillary glucose (n = 423).
j Prevalence of diabetic retinopathy was 31.6% among those measured for random capillary glucose (n = 402).
k Prevalence of diabetic retinopathy was 32.5% among those measured for fasting venous glucose (n = 418).
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(continued)
Table 1. Prevalence of Diabetic Retinopathya by Sociodemographic and Clinical Characteristics, and Means/Medians for Other Clinical Characteristics by Diabetic
Retinopathya Status of Study Population in 3 Low-Income Municipalities, Mexico, 2014–2016
Characteristics Total (N = 1,000)
Has Diabetic Retinopathy, %
(n = 317)
Does Not Have Diabetic
Retinopathy, % (n = 683) P Valueb
No 345 20.0 80.0
General hypertensionc (previous diagnosis or measurement of blood pressure ≥140/≥90 mm Hg)
Yes 524 35.5 64.5
.006
No 469 27.3 72.7
Physical activity used to control diabetesg, h
Yes 272 26.8 73.2
.01
No 554 35.6 64.4
Diet used to control diabetesg, h
Yes 345 30.4 69.6
.23
No 483 34.4 65.6
Age, mean (SD), yc 57.2 (11.0) 57.9 (9.3) 56.9 (11.7) .16
Time since diabetes diagnosis,
median (IQR), yc
7.0 (3.0–14.0) 13.0 (8.0–18.0) 5.0 (2.0–10.0) <.001
Fasting capillary glucose, median
(IQR), mg/dLi
149.0 (118.0–221.0) 194.5 (140.0–243.0) 137.0 (113.0–195.0) <.001
Random capillary glucose, median
(IQR), mg/dLj
214.5 (155.0- 295.0) 240.0 (182.0–325.0) 196.0 (148.0–273.0) <.001
Fasting venous glucose, median (IQR),
mg/dLk
153.0 (117.0–219.0) 198.0 (146.0–252.0) 135.5 (110.0–197.0) <.001
Insulin, median (IQR), µIU/mLf 9.75 (6.7–13.8) 10.4 (7.3–15.6) 9.5 (6.6–13.7) .48
Systolic blood pressure, median (IQR),
mm Hgc
127.5 (115.5–142.0) 131.5 (118.5–147.5) 126.5 (114.0–140.0) <.001
Diastolic blood pressure, median
(IQR), mm Hgc
72.0 (64.0–79.5) 72.5 (65.0–80.5) 71.5 (63.5–79.5) .19
Abbreviations: HOMA, homeostasis model assessment; IMSS, the Mexican Social Security Institute (Spanish: Instituto Mexicano del Seguro Social); IQR, interquart-
ile range; ISSSTE, the Institute for Social Security and Services for State Workers (Spanish: Instituto de Seguridad y Servicios Sociales de los Trabajadores del Es-
tado).
a Diabetic retinopathy classification according to Revised English Diabetic Eye Screening Program Grading System (grade 1, grade 2, or grade 3) (25).
b χ2 test (contingency tables for more than 2 categories or proportion comparison), Student t test, or Mann–Whitney U test.
c The percentage of participants with missing data was <5.0% or with complete information.
d Socioeconomic index developed by using first principal component methodology.
e Prevalence of diabetic retinopathy was 32.5% among those measured for triglycerides, total cholesterol, and high-density lipoprotein cholesterol (n = 418).
f Prevalence of diabetic retinopathy was 25.9% among those measured for insulin (n = 112).
g The percentage of participants with missing data ≥5.0%.
h Determined by answer to question “Do you have any other treatment for sugar control?” Exercise (no/yes) and diet (yes/no) were provided as possible responses.
i Prevalence of diabetic retinopathy was 30.7% among those measured for fasting capillary glucose (n = 423).
j Prevalence of diabetic retinopathy was 31.6% among those measured for random capillary glucose (n = 402).
k Prevalence of diabetic retinopathy was 32.5% among those measured for fasting venous glucose (n = 418).
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Table 2. Predictive Multivariate Model in the Development of a Screening Tool for Diabetic Retinopathy for Use in Low-Income Communities, Mexico, 2014–2016
Risk Factors for Diabetic Retinopathy
Predictive Probit Model (n = 939)a
Coefficient (SE) P Valueb Estimated Probabilityc, % (95% CI) P Valueb
Time since diabetes diagnosis, y
<5  —d  —d 11.4 (7.9–14.9)  —d
5 to <10 0.55 (0.13) <.001 24.9 (19.2–30.6) <.001
10 to <15 1.16 (0.14) <.001 46.6 (39.4–53.9) <.001
≥15 1.41 (0.13) <.001 56.0 (49.5–62.6) <.001
High blood glucose (fasting venous or capillary glucose ≥126 mg/dL or random capillary glucose ≥200 mg/dL)
No  —d  —d 23.9 (19.5–28.3)  —d
Yes 0.41 (0.10) <.001 35.6 (32.2–39.0) <.001
High systolic blood pressure (≥140 mm Hg)
No  —d  —d 29.3 (26.2–32.4)  —d
Yes 0.27 (0.10) .007 37.4 (32.3–42.5) .007
Physical activity used to control diabetese
No  —d  —d 34.8 (31.4–38.2)  —d
Yes −0.33 (0.11) .002 25.4 (20.9–30.0) .002
Constant −1.48 (0.12) <.001  — d  —d
Abbreviations: CI, confidence interval; SE, standard error.
a Multivariate probit model with any grade of diabetic retinopathy (grade 1, grade 2, or grade 3) as dependent variable according to Revised English Diabetic Eye
Screening Program Grading System (25).
b P value for probit coefficients or for comparison of estimated probabilities among categories and lowest category of different variables.
c Obtained by predictive margins.
d Lowest category or estimated probability of constant.
e Determined by answer to question “Do you have any other treatment for sugar control?” Exercise (no/yes) was provided as a possible response.
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Table 3. Cross-Validation Analysis (k = 10) of Predictive Probit Model (n = 939) in the Development of a Screening Tool for Diabetic Retinopathy for Use in Low-
Income Communities, Mexico, 2014–2016
Iteration Training Data Set (n ~ 90%), AUC ROC (95% CI) Validation Data Set (n ~ 10%), AUC ROC (95% CI)
1 0.775 (0.742–0.809) 0.806 (0.720–0.891)
2 0.780 (0.747–0.813) 0.784 (0.690–0.877)
3 0.783 (0.751–0.815) 0.756 (0.642–0.870)
4 0.782 (0.750–0.814) 0.764 (0.659–0.869)
5 0.777 (0.744–0.810) 0.806 (0.712–0.899)
6 0.779 (0.747–0.811) 0.780 (0.664–0.896)
7 0.786 (0.754–0.818) 0.723 (0.603–0.842)
8 0.783 (0.750–0.815) 0.754 (0.653–0.855)
9 0.774 (0.740–0.807) 0.830 (0.746–0.914)
10 0.778 (0.746–0.811) 0.776 (0.672–0.881)
Average 0.780 0.778
Abbreviations: AUC ROC, area under the receiver operating characteristic curve; CI, confidence interval.
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Table 4. Diagnostic Tests for Cut Points of a Screening Tool for Diabetic Retinopathy for Use in Low-Income Communities, by Misclassification-Cost Ratio and Vari-
ous Scenarios of Diabetic Retinopathy Prevalence, Mexico, 2014–2016
Misclassification Cost Ratiob
Predictive Probit Model (n = 939)a
Sensitivity, % Specificity, % Positive Predictive Value, % Negative Predictive Value, % z Cut Point
Diabetic retinopathy prevalence of 31.7% (observed)
1 56.4 83.0 60.7 80.4 −0.046
4 82.9 61.9 50.3 88.6 −0.640
10 96.6 28.7 38.7 94.9 −1.209
Diabetic retinopathy prevalence of 35.0%
1 60.1 81.1 63.2 79.1 −0.121
4 90.9 45.9 47.5 90.4 −1.017
10 96.6 28.7 42.2 94.1 −1.209
Diabetic retinopathy prevalence of 40.0%
1 67.8 76.4 65.7 78.1 −0.305
4 90.9 45.9 52.8 88.4 −1.017
10 96.6 28.7 47.5 92.8 −1.209
Diabetic retinopathy prevalence of 45.0%
1 71.5 74.0 69.2 76.0 −0.374
4 96.0 31.7 53.5 90.6 −1.190
10 96.6 28.7 52.6 91.3 −1.209
a Multivariate probit model with any grade of diabetic retinopathy (grade 1, grade 2, or grade 3) as dependent variable according to Revised English Diabetic Eye
Screening Program Grading System (25). Estimated coefficients from the multivariate probit model are shown in Table 2.
b Misclassification-cost ratio = cost of classification of false negatives divided by cost of classification of false positives. Ratios of 1, 4, and 10 were used, assum-
ing that false-negative classification of a person receiving diabetic retinopathy screening would generate greater health costs than would a false-positive classifica-
tion.
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